Introduction
The allocation of deceased donor livers for transplantation in the United States has undergone a major transformation since implementation of the model for end-stage liver disease (MELD) and the pediatric model for end-stage liver disease (PELD). February 27, 2007, marked the 5-year anniversary of MELD/PELD, and data collected during the past 5 years allow for assessment of the system after transplant professionals have adjusted to and accumulated experience with it. In addition to the documentation of trends in the liver waiting list, deceased and living donor transplant recipients, and posttransplant outcomes, special sections on donation after cardiac death and patients with hepatocellular carcinoma are included. Intestinal transplantation is commonly performed in combination with other organs, most often with liver or liver and pancreas, and has continued to offer options for individuals with intestine failure. Trends in intestinal transplantation are described in the article following liver transplantation. . As in past years, men outnumbered women on the waiting list (males 61%, females 40%). The distribution of blood types among waiting list candidates was similar to previous years; 50% had blood group O, 38% had blood group A, 11% had blood group B and 2% had blood group AB. Compared with the late nineties, there were fewer candidates who were female, had blood type O or had previous liver transplants.
Liver waiting list

Primary diagnosis at listing and previous transplant:
The distribution of liver transplant candidates across the major diagnostic categories of liver disease in 2006 was similar to previous years. Noncholestatic cirrhosis was the largest diagnostic category with 73% of candidates on the waiting list. Cholestatic cirrhosis was the second largest grouping with 10%, followed by 'other' with 9%. Acute hepatic necrosis was the primary diagnostic category for 4% of the waiting list, while biliary atre- sia, metabolic diseases and malignant neoplasms each accounted for less than 2% of the waiting list. The fraction of the waiting list with a previous liver transplant was 3% in 2006, which was less than in the late 1990s. 
MELD/PELD scores:
Waiting time and median time to transplant:
By the end of 2006, about 64% (17.5% waiting 1-<2 years and 46.6% waiting 2+ years) of the waiting list with active status had been listed for more than 1 year with almost 47% listed for more than 2 years. Figure 3 shows the median time to transplant (TT) among candidates on the waiting list that were initially listed in the given calendar year. The median time to transplant is calculated as the number of days until half of the new waiting list registrants in the calendar year have received a transplant. Median TT for liver waiting list candidates decreased substantially after the implementation of MELD/PELD in 2002 when the median TT was 981 days. Figure 4 ) and varied according to demographic and medical factors. Patients older than 65 years carried a greater risk of death. However, children less than 5 years old carried a greater risk of death than older patients, while children less than 1-year old had the highest rate of all age groups (879 deaths per 1000 patient-years). All ethnic groups experienced declining death rates over the past 10 years ( Figure 5 Patient events on the waiting list: Figure 6 shows the incidence of transplant or death over the ensuing 3 months for adults on the waiting list on Age: Figure 7 shows the age distribution for recipients of DDLT across the past decade. The number of pediatric (less than 18 years of age) deceased donor recipients has not changed much and was only 8% of all DDLT in 2006 (6% for children under 11 and 2% for children age 11-17). The largest increase in adult DDLT since 1997 has been in the '50-64' and '65+' age groups, with DDLT declining slightly in the younger adult categories over the years. In 2005, patients receiving transplants at MELD scores of 15-20 had the lowest 1-year death rates for adults (90 deaths per 1000 patient-years). Patients transplanted at MELD 6-10 (159) and 11-14 (120) had higher death rates than MELD 15-20. The increased death rates for the lowest MELD categories may be due to the higher proportion of these patients receiving higher risk grafts. Generally, PELD patients had lower death rates than MELD patients. However, rates were similar at the high ranges of Liver transplant recipient survival: Among the most recent transplant cohorts for whom follow-up data were available, adjusted patient survival following DDLT was 94% at 3 months, 88% at 1 year and 79% at 3 years. Survival rates were adjusted for recipient age, gender, race, diagnosis and laboratory MELD/PELD score at transplant. Since the cohort for 5-year survival includes pre-MELD era transplant recipients, only survival for 3 months, 1 year and 3 years could be calculated with MELD as a covariate. The adjusted patient survival for LDLT was not statistically different from DDLT at 95% for 3 months (p = 0.24), 90% for 1 year (p = 0.18) and 82% for 3 years (p = 0.08). Adjusted graft survival was somewhat lower than the adjusted patient survival. For DDLT, graft survival was 90% at 3 months, 83% at 1 year and 74% at 3 years. These rates were not statistically different for LDLT with 89% at 3 months (p = 0.65), 83% at 1 year (p = 0.92) and 75% at 3 years (p = 0.56).
Age: Adjusted patient survival varies with the age of the recipient. Patient survival for recipients of DDLT at 3 months was highest for adolescents (age 11-17) at 97%, followed by those less than 1-year old (96%). The lowest survival was for the oldest age group (adults aged 65 and older) at 90%. For LDLT, those aged 65 and older had the lowest 3-month survival at 86%, followed by adults aged 50-64 at 94%. At 1 year, patient survival among DDLT recipients was lowest for those aged 65 and older at 80%, followed by adults aged 50-64 at 87% and highest for children under age 1 at 94% and adolescents aged 11-17 at 94%. LDLT recipients aged 65 and older also had the lowest survival rate at 1 year at 84%, followed by adults aged 50-64 at 86%. It was highest for adults aged 18-34 at 96%. At 3 years, the highest survival rate for DDLT was 90% for children less than 1 year old and for LDLT was 92% for adolescents aged 11-17. The lowest survival was for adults aged 65 and older for both types of transplants (DDLT: 70%, LDLT: 73%).
Race/ethnicity and gender: Adjusted patient survival varied with race. For DDLT, survival was similar across races at 3 months (between 91% and 94% for all groups) and 1 year (between 86% and 88% for all groups). Differences appeared at 3 years, with African American DDLT recipients having the lowest survival rate (74%) and Asians having the highest (82%). Among LDLT, African Americans had better survival than whites at 3 months (100% vs. 95%) and at 1 year (96% vs. 90%), but lower survival at 3 years (78% vs. 81%). Hispanic LDLT had the lowest
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survival rate at 3 months (92%) and 1 year (86%), but the highest survival rate at 3 years (86%). Men and women who received DDLT had similar survival rates at 3 months (93% vs. 94%), 1 year (87% vs. 88%) and 3 years (79% for both). The results were similar for LDLT with 95% for both at 3 months, 89% for men and 91% for women at 1 year, and 81% for men and 84% for women at 3 years.
Medical factors: At 3 months, adjusted patient survival for DDLT among primary diagnosis categories at transplant was between 90% (acute hepatic necrosis) and 95% (cholestatic liver disease). For LDLT recipients, adjusted patient survival ranged from 100% for acute hepatic necrosis to 88% for metabolic disorders. At 1 year, the adjusted patient survival rates for DDLT were: biliary atresia (91%), cholestatic liver disease (90%), metabolic diseases (88%), noncholestatic cirrhosis (88%), acute hepatic necrosis (87%), 'other' disorders (86%) and malignant neoplasms (83%). For LDLT, adjusted patient survival at 1 year was slightly higher and a different pattern emerged: acute hepatic necrosis (96%), cholestatic liver disease (92%), 'other' diagnoses (92%), noncholestatic cirrhosis (89%), metabolic diseases (82%) and malignant neoplasms (76%). There were not enough data to estimate a 1-year rate for biliary atresia among LDLT. Figure 10 shows 3-year adjusted survival rates by diagnostic categories for DDLT and LDLT. The distribution of adjusted survival rates for DDLT is similar at 3 years to 1 year: biliary atresia (87%), cholestatic liver disease (85%), metabolic disorders (84%), 'other' diagnoses (79%) and noncholestatic cirrhosis (79%), acute hepatic necrosis (78%) and malignant neoplasms (71%). Three-year patient survival for malignant neoplasms is significantly lower than all of the other diagnoses at p < 0.001. Patterns differed somewhat for LDLT. At 3 years, adjusted survival for LDLT from highest to lowest was: biliary atresia (93%), cholestatic liver disease (90%), acute hepatic 
Donation after cardiac death (DCD) liver transplants
In 2006, the number of livers transplanted from DCD continued to increase numerically and proportionately, although the increase from 2005 to 2006 was less than in years past (Table 1) . Since 2000, livers from DCD have come more frequently from donors who were: aged 18-49 years (p < 0.001); more often male (p < 0.001); more often white and less often African American or Hispanic (p < 0.001); and more likely to have anoxia and less likely to have stroke as a cause of death (p < 0.001) compared with donation after brain death (DBD) ( Table 2 ). Over this same time frame, recipients of DCD livers were less often children (p < 0.001), more likely male (p = 0.01), and slightly more likely to be white than any other race/ethnic group (p < 0.001). They had slightly greater body mass index (p < 0.001), were less likely to be in the ICU or hospitalized (p < 0.001), and more likely to have noncholestatic cirrhosis (p < 0.001) as their primary diagnosis than recipients of livers from DBD (Table 3) . A higher percentage of DCD livers were shared compared with DBD grafts, and they were more likely to be used in transplants with identical blood type. Interestingly, the cold ischemia time did not differ between DCD and DBD livers (p = 0.65). A smaller proportion of DCD grafts were used for candidates with higher MELD/PELD scores compared with DBD livers, although these differences were modest (Table 4) .
Previous reports have documented inferior liver graft survival for grafts procured from DCD donors compared with DBD organs (1, 2) . This updated analysis also found significantly inferior graft survival at 3-month, 1-year and 3-year time points (Figure 11 ). Covariates in these models included: all donor characteristics in Table 2 ; all recipient characteristics in Table 3 (plus diabetes); preexisting candidate malignancies; Status 1/1A/1B at transplant; recipient previous abdominal surgery; recipient pretransplant dialysis; MELD/PELD at transplant; recipient inotropic blood pressure support; history of portal vein thrombosis; hepatitis B positive; hepatitis C positive; partial or split liver graft; donor location; ABO compatibility and cold ischemia time. Thus, even with this extensive risk adjustment, the current data suggest that DCD liver grafts have inferior graft survival results. 
Liver transplantation for candidates with HCC
The first liver transplants were performed for patients with extensive primary hepatocellular carcinoma (HCC) (3). Initial results were complicated by technical problems and early recurrences that dampened enthusiasm for treating malignancies with liver transplantation. In the mid 1990s, teams from France (4) and Italy (5) published excellent results for liver transplantation applied to patients with welldefined, early-stage HCC. The group from Milan found a low risk for HCC recurrence after liver transplantation for single tumors less than 5 cm in size, and up to three tumors with the largest being no larger than 3 cm (3). These 'Milan criteria' formed the basis of the HCC policy contained within the MELD-based priority system (6) . In this policy, candidates with HCC meeting Milan criteria were Freeman et al. allowed extra priority on the waiting list because their risk of cancer progression was estimated to be much higher than the mortality risk predicted by their laboratory-based MELD score. Initially, policymakers estimated that the cancer progression risk for patients with Stage 2 HCC was 30% at 3 months, which equated to a MELD mortality risk score of 29, and that the risk for Stage 1 HCC was 15%, equating to a MELD score of 24. Subsequent studies suggested that these progression risk estimates were too high and therefore policy was revised downward to remove extra priority for Stage 1 disease and reduce the HCC Stage 2 priority to a MELD score of 22, equivalent to a 15% risk of waiting list death. To our knowledge, this is the first comprehensive analysis of the effects of the HCC allocation policies within the MELD/PELD system to be published. transplants sooner than M20-29 candidates (7 regions), although the difference is small for several of these regions. (Figure 14 ). Unlike Figure  6 , which looked only at death, Figure 15 looks at removal rates for death or being too sick for a transplant (which in the case of HCC, means cancer progression or so-called waiting list 'drop out'). These 'drop out' rates were much lower for HCC candidates than for those non-HCC candidates prioritized by MELD without exceptions. (Figure 16 ).
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The reporting of ablation did not vary greatly across demographic groups (Table 6 ). Older individuals had more ablation reported than average (65% for age 65+ vs. 55% 
HCC recipient characteristics:
The proportion of deceased donor transplants to HCC candidates (any stage granted an exception, not just T2) has remained stable over the MELD era years (16-18%, see Figure 17 ). Only a small fraction of the transplants performed for HCC have been done with living donor grafts, in keeping with similar trends for nonmalignant liver transplant indications (Figure 18 ). Deceased donor transplant rates per 1000 patient-years for candidates receiving HCC exceptions are approximately three to four times higher than the rates for non-HCC patients (full range of MELD scores) ( Table 7) . Across racial groups in 2006, African Americans had the highest transplant rates per 1000 patient-years for both HCC candidates (1572) and non-HCC candidates (530), while Asians had the lowest (851 for HCC and 239 for non-HCC). For non-HCC candidates, 'other' race had the second-highest rate at 349, followed by whites (312) and Hispanics (279). For HCC candidates the order was: whites (1424), Hispanics (1124) and 'other' (1048). Transplant rates in 2006 for HCC candidates varied greatly across OPTN regions from a high of 3165 in Region 3 to a low of 683 in Region 1, as did transplant rates for non-HCC candidates from a high of 829 in Region 3 to a low of 139 in Region 1. Figure 19 and Figure 20 show adjusted graft and patient survival for HCC and non-HCC recipients when MELD at transplant and other covariates are included in the survival models. The cohort used to calculate 5-year survival includes pre-MELD era transplants. Therefore, 5-year survival cannot be calculated at this time. Graft survival is higher for recipients with HCC than those without HCC at 3 months (92% vs. 90%, p < 0.001), the same for HCC and non-HCC recipients at 1 year (83% for both, p = 0.71) and lower for HCC recipients than non-HCC recipients at 3 years (70% vs. 75%, p < 0.001). Patient survival is the same at 3 months (94% for both, p = 0.65) but significantly higher for non-HCC recipients at 1 year (88% vs. 85%, p = 0.003) and 3 years (81% vs. 74%, p < 0.001). It is also informative to compare survival of HCC T2 recipients to that of non-HCC recipients with MELD scores similar to the HCC exception level. HCC T2 recipients had greater survival at 3 months than MELD = 29 recipients, but was not statistically different than MELD = 22 or MELD = 24 recipients (at 3 months, 1 year or 3 years, data not shown) or MELD = 29 recipients at 1 year or 3 years.
Graft and patient survival:
Consistent with an increasing proportion of HCC candidates being treated with AT before transplant, there is an increasing fraction of transplant recipients with any ablation treatment reported, and Figure 21 shows the type of AT among those reporting any AT. Recipients with HCC exceptions for whom an AT was reported have similar patient and graft survival at 3 months (p = 0.33 graft and p = 0.48 patient) and 1 year after transplantation (p = 0.33 and p = 0.65). However, at 3 years after transplant, recipients given AT have superior graft (76% vs. 71%, p = 0.03) and patient (79% vs. 75%, p = 0.03) survival, compared with HCC recipients for whom no AT was reported (Figure 22 and Figure 23 ). The reported type of ablation does not appear to have any association with improved or diminished patient or graft survival, although small sample sizes limit the precision of these estimates.
Continuing to use a portion of the deceased donor pool for liver transplantation for HCC remains controversial. Data presented above suggest, at least by some measures, that candidates receiving HCC exceptions have increased access to the deceased donor pool relative to their non-HCC counterparts and that there is considerable variation among the OPTN regions in this area (Table 7) . For HCC candidates, a more evidence-based system should be developed to assess their need for liver transplant that better equates their risk of removal from the waiting list as too sick to transplant (i.e. the cancer is too widespread for transplant) with the risk of death for nonmalignant candidates. One such proposal, the HCC MELD score could meet this requirement. However, this will not equalize other geographic disparities among the regions. A move toward better standardization of regional review board processes might be required.
Summary
In terms of number of patients being treated and success rates, progress continues in all aspects of liver transplantation. Over the previous decade, patient and graft survival rates remained unchanged, despite increasingly more ill and older candidates having received DDLT. Introduction of the MELD/PELD system has reduced waiting list deaths and waiting list numbers have also decreased due to the removal of waiting time as a driving force for priority. As a result, median times to transplant for patients prioritized by MELD/PELD have been significantly reduced. The current data suggest that LDLT outcomes are equal to DDLT when severity of candidate disease is accounted for in survival models. Wider application of DCD liver transplantation has increased access to transplantation, but the clearly inferior results with DCD liver grafts will need further monitoring. Given the very high waiting list mortality risk for patients with high MELD scores, continued application of DCD is justified for these candidates. But given the clear increased risk of graft failure for DCD livers, use of these grafts has to be weighed against the risk of dying on the waiting list without receiving a liver graft for each individual patient. Emerging evidence suggests that despite remaining geographic differences, previous adjustments in HCC priority policy have reduced some disparities in DDLT ac- cess among HCC and non-HCC candidates, but HCC candidates still enjoy much higher transplant rates compared with non-HCC patients.
Intestine transplantation
Intestine transplantation has shown remarkable advancement over the past decade in not only volume of transplants performed but also in outcomes. There are many areas in which intestine transplant still lags behind other solid organ transplants. The OPTN and the Scientific Registry of Transplant Recipients (SRTR) Annual Report data analysis can be helpful in assessing results and areas of improvement. This is particularly true in regards to candidate listing, donor characteristics, recipient outcomes and immunotherapy. These topics, as highlighted by the data tables, will be discussed in this section. the age of 6 years (57%), white (66%) and male (60%) (Figure 25 ). The most substantial change in the waiting list characteristics over the past decade has been the percentage of candidates with a prior organ transplant-including intestine. This group has nearly tripled from 3% in 1997 to 14% in 2006. Although candidates diagnosed with short gut syndrome still represent the majority of waiting list primary diagnoses, the absolute percentage decreased from 77% in 1997 to 54% in 2006. There was no change in the percentage of candidates with the diagnosis of 'functional bowel problems' but percentages of candidates with 'other' diagnosis has increased from 9% to 32%. Despite the seemingly small numbers of intestine candidates on the waiting list, mortality remains high ( Figure 27 ). This mortality rate, expressed as the death rate per 1000 patient-years at risk, is the highest among all solid organ transplants including the liver (Figure 4 ) (8) . Overall, the death rate for intestine candidates has improved from its peak in 1997 at 586 to its current level of 265. The lowest death rate for intestine candidates was 253 in 2000. These rates are still more than double that for candidates of other solid organ transplants including kidney (70), pancreas alone (47), pancreas after kidney (31), kidney-pancreas (96), liver (115), heart (151), lung (97) and heart-lung (142). age group has had the worst problem with mortality rates ranging from 878 to 914 between 1997 and 2005. The data from 2006 indicate a mortality rate of only 99 (death rate per 1000 patient-years listed). However, given the small sample size in this age range, this statistic was based on 1 death among 39 candidates. Only time will tell if this is a sustainable improvement in survival or just a 1-year phenomenon due to random chance. Ongoing substantiation of these data is critical.
Intestine waiting list
Race/ethnicity may also play a role in waiting list mortality. Whites and African Americans had mortality rates roughly similar to the total group, whereas Asians had a rate of 145 and Hispanics had the highest rate (399). Blood groups differed in mortality, with groups O and A having mortality rates roughly equal to the mean. Groups B and AB were higher than the mean at 319 and 338, respectively. The primary diagnosis also affected waiting list mortality rates with short gut syndrome and functional bowel problems having lower death rates (220 and 113, respectively) compared to 'other' and unknown with higher death rates (308 and 358, respectively).
These results have not gone unnoticed. In March 2003, the OPTN implemented several policy changes that a) gave combined liver-intestine candidates additional MELD/PELD points equivalent to 10% waiting list mortality risk at 3 months (Policy 3.6.4.7), b) allowed the liver to be allocated off the intestine list after regional Status 1 liver candidates are offered the organ (Policy 3.11.4) and c) allocated pediatric donor organs to pediatric recipients after Status 1 liver candidates are offered the organ (Policy 3.6). Since these policy changes have not led to a decrease in the intestine waiting list mortality, additional policy amendments were implemented in June 2007 including the addition of 23 extra MELD/PELD points to combined liver intestine candidates (Policy 3.6.4.7) (9).
Intestine procurement
Because waiting list mortality rates for intestine candidates are extremely high, it is important to focus on the intestine donor and increase the donor pool. It should be noted that based on these data sets there were 8024 deceased donors (of any organ) in the USA in 2006; this represents a 46% increase since 1997. During the same interval, there was a 156% increase in the number of deceased intestine donors up to an all time high of 184. There were also a few living-donor intestine transplants performed in 2006 (n = 3).
Intestine recipients
Overall, the number of intestine recipients has increased over the past decade. Intestine recipients include those that receive an isolated intestine graft as well as those that receive the intestine as part of a multi-organ graft complex. In 2006, there were 57 intestine alone transplants from deceased donors, representing a 171% increase since 1997 and 114 multi-organ transplants involving intestines. During the same interval, there was a 187% increase in the number of multi-organ transplants performed (n = 566). While the majority of these were kidney-liver (71%), organ combinations that include the intestine were the second most common. These included: kidney-liver-intestine (n = 1), kidney-pancreas-intestine (n = 1), kidney-pancreas-liverintestine (n = 7), kidney-intestine (n = 1), liver-intestine (n = 35), pancreas-intestine (n = 9) and pancreas-liver-intestine (n = 60).
There have been few shifts in the demographic and medical characteristics of recipients over the past decade, although the percentage of recipients aged 1 year or less and 50-64 years increased, whereas the percentage of recipients between 1 and 10 years of age decreased. Females accounted for 40% of the waiting list candidates, and made up 52% of transplant recipients. The percentage of recipients with a prior intestine transplant decreased from 11% in 2005 to 9% in 2006. Private insurance providers covered 45% of recipients and public providers such as Medicare and Medicaid accounted for 8% and 39%, respectively. Remarkably, 64% of recipients were not hospitalized at transplant and the vast majority was not on mechanical support. Most recipients (70%) had a primary diagnosis of short gut syndrome with little change over the past decade. Ischemia times demonstrated an important trend, notably a decrease from 16% in 1997 to 3% in 2006 in cold ischemia time over 10 h. There has been a concomitant rise in the '0-5-h' group from 3% in 1997 to 18% in 2006. This represents a very positive trend, either indicating a more aggressive initiative of organ procurement organizations to identify and place intestine grafts or the emergence of intestine transplant programs.
Immunosuppressive practices have changed significantly since 1997. Use of any induction therapy was uncommon in 1997, with only 8% of transplant recipients reporting any induction therapy. By 2000, 69% of transplant recipients reported using induction therapy, with daclizumab (Zenapax, Roche, Nutley, NJ) being the most common induction agent, used in 55% of cases. In 2003 it shifted with 46% using rabbit antithymocyte globulin (ATG) (Thymoglobulin, Genzyme Corp., Cambridge, MA). By 2006, induction therapy was evenly distributed among muromonab-CD3 (OKT3, Orthobiotech, Bridgewater, NJ) (14%), rabbit ATG (18%), daclizumab (17%) and alemtuzumab (Campath-1H, Genzyme Corp., Cambridge, MA) (21%). Maintenance immunosuppression at discharge for intestinal recipients was mostly tacrolimus (Prograf, Astellas, Tokyo, Japan) and corticosteroids (53%). Recipients discharged after transplant on a steroid-free regimen were more likely to have received induction rabbit ATG or alemtuzumab. At 1-year posttransplant, intestine recipients were maintained with either tacrolimus alone (37%) or tacrolimus plus steroids (36%) indicating a wean of the maintenance immunosuppression regimen. For rejection therapy in the first year after transplant, intestine recipients received steroids in
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86% of cases with antibody therapy added in 40%. The most common antibody therapy used for rejection was muromonab-CD3.
Intestinal transplantation results appear to be improving, particularly in the short term as demonstrated by these outcome measures-the death rate per 1000 patient-years at risk as well as the more commonly quoted patient and graft survival rates. Using the death rate per 1000 patientyears at risk in the first year after transplant, the overall rate for intestine recipients was 245 in 2006 (for transplants done in 2005). Based on this same measure, the groups of intestine recipients at higher risk for death are the: 'less than 1 year' age group (rate 447) and '35-49 year' age group (rate 315); whites (277); females (279); recipients of blood group O (293); those with a prior transplant of any organ (335); and those hospitalized prior to transplant (303 for hospitalized but not in the ICU and 360 for ICU). Recipients of donors less than 1 year of age had a much higher death rate (364).
Survival after intestinal transplantation has shown steady improvement since 1997. The 1-year adjusted graft survival has increased from 52 ± 6.3% in 1997 to 75 ± 3.4% in 2005. Similarly, the 1-year adjusted patient survival has improved from 57 ± 6.5% in 1997 to 80 ± 3.3% in 2005. To accurately analyze survival, it is important to separate intestine alone and liver-intestine transplants. For recipients of intestine alone, unadjusted patient survival was 81% for 1 year, 67% for 3 years, 54% for 5 years and 43% for 10 years. Graft survival during the same intervals was 73%, 54%, 37% and 23%. For comparison, patient survival for recipients of liver-intestine transplants was 76% for 1 year, 70% for 3 years, 58% for 5 years and 38% for 10 years, while intestine graft survival for the same intervals was 75%, 69%, 56% and 36%. There does not appear to be a significant difference between patient or graft survival when comparing intestine alone to liverintestine. The lowest adjusted 1-year graft survival rates are seen in the groups aged '65+ years' and 'less than 1 year'; and the race/ethnicity group 'other/multi-race'. Despite these numbers, the number of recipients living with a functional intestine transplant is at its highest level (n = 514) since 1997.
Summary
As a field, intestinal transplantation has made great strides over the past decade. Still, there are major issues to address. Improving waiting list mortality risks for candidates on the intestine list is imperative. The current data are unacceptably high. Implementation of national organ allocation policies are underway to improve this situation, however, careful data analysis is needed to verify that these policy changes are an improvement. It is not all together clear as to why mortality rates are so high. Certainly, specific donor and recipient factors are involved, some of which have been identified through these data sets. Additionally, these data indicate the number of intestine transplants performed is at an all time high and would be expected to continue to increase. The optimal immunotherapeutic regimen is evolving and currently includes the use of induction agents. Although survival is lower than that typically seen after other solid organ transplants, survival after intestine transplantation is improving.
Conclusion
Overall, 2006 represented further progress in the field of liver and intestinal transplantation. More patients are receiving transplants in large part due to the success of the organ donation breakthrough collaborative. In addition, there is evidence that patients most in need of these life saving organs are more frequently getting access to these transplants since death rates on the waiting list are decreasing. These improved waiting list results have not been compromised by reduced survival rates. Geographic and demographic differences remain problematic, however, and should draw increasing scientific inquiry. Many challenges remain in the effort to continue improving the liver and intestine transplantation field.
